Pure Global
NCT06221462

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer

Neoadjuvant Sintilimab Plus Anlotinib Therapy in IB-IIIB Resectable Non-small Cell Lung Cancer (PRIORITY): a Prospective Single Center, Open Label, Phase II Study
Ningbo No.2 Hospital·Phase 2·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Carcinoma, Non-Small-Cell Lung
Drug/Device/Intervention
Sintilimab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Ningbo No.2 Hospital
Timeline & enrollment
Phase
Phase 2
Start date
Feb 01, 2024
End date
Feb 01, 2030
Enrollment
30 participants
Primary outcome

major pathological response (MPR)

Summary

This is a prospective single-center, open-label, phase II study evaluating the efficacy of
 sintilimab plus anlotinib as a neoadjuvant regimen in the treatment of IB-IIIB resectable
 non-small cell lung cancer.

ICD-10 classifications
Carcinoma in situ: Bronchus and lungSecondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06221462
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06221462 through Pure Global AI's free database. This Phase 2 trial is sponsored by Ningbo No.2 Hospital and is currently Not yet recruiting. The study focuses on Carcinoma, Non-Small-Cell Lung. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.